Generating high-quality single-cell data requires samples with high cell viability and minimum to no alteration of their true biological state. This is especially challenging for single-cell workflows, which often require long processing and handling times. Further complicating the above are studies that require shipping or transferring of samples across different sites and locations. Keeping these needs in mind, a novel cell preservation solution was developed that works across a variety of single-cell applications including flow cytometry, RNA-seq, CITE-seq and qPCR.
This webcast will showcase two sets of data powered by this novel cell preservation solution. First, learn how it enabled researchers to explore the tumour microenvironment (TME) and its influence on immunomodulatory agents. A novel approach to examine immune responses in the TME with small tumour samples will be presented. This approach has now helped uncover the balance of PD-1 expression between tumour-infiltrating effector cells and regulatory T (Treg) cells as a biomarker for evaluating the effects of PD-1/PD-L1 blockade immunotherapy.
The second set of data will walk through a step-by-step approach for conducting single-cell multiomics studies to generate high-quality data with preserved samples. Learn how to preserve and ship your samples for up to 72 hours at 4°C and still generate RNA-seq, CITE-seq and TCR/BCR single-cell data with confidence.
Learn how to:
• Preserve and ship cells and tissues for multisite studies
• Employ cell preservation technologies critical to discovery studies using tumour samples
• Use a single preservation solution to support flow cytometry, RNA-seq and CITE-seq research
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by BD Biosciences, who retains sole responsibility for content. About this content.
Speakers
Hiroyoshi Nishikawa, Chief, Division of Cancer Immunology, National Cancer Center Japan
Hiroyoshi Nishikawa, MD, PhD, has continuously studied the role of immunosuppressive mechanisms, particularly regulatory T cells in tumor immunity. He is involved in both basic research of immune regulation, particularly immune tolerance induced by regulatory T cells, and translational research developing novel cancer immunotherapies targeting regulatory T cells. In 2023, Dr. Nishikawa was honored as one of the Highly Cited Researchers 2023 by Clarivate Analytics fourth consecutive year, following his recognition from 2020. He continues to be at the forefront of cancer immunology research.
Cynthia Sakofsky, Staff Scientist, BD Biosciences
Cynthia Sakofsky, PhD, has over 15 years of research experience working in the field of genomics, which she now brings to the advancement of single-cell biotechnology. Cynthia is currently a staff scientist at BD Biosciences, where she drives novel application and technology development projects within the single-cell multiomics platform. She earned her PhD in Molecular Genetics at the University of Cincinnati and continued her postdoctoral research at the National Institutes of Health (NIH).
Moderator
Sarah Hiddleston, Nature Research Custom Media
Sarah Hiddleston is a freelance journalist who has worked with Nature Research Custom Media since 2015. Previously, Sarah worked for a decade in Madras (Chennai), India, specialising in health, pharmaceutical and environmental stories. Sarah holds an MA in Investigative Journalism from City University London, an MSc in Political Theory from the London School of Economics, and an undergraduate degree in History from the University of Cambridge, UK.
